Alkaptonuria: Leading to the treasure in exceptions

JIMD Reports

Volumn 5, Issue , 2012, Pages 49-57

  Cox, Timothy M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Acute porphyria; Fabry disease; Homogentisic acid; Inborn error; Orphan medicinal product

Indexed keywords

EID: 84887905912     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2011_93     Document Type: Chapter

References (52)

1. Anikster Y, Nyhan WL, Gahl WA (1998) NTBC and alkaptonuria. Am J Hum Genet 63:920–921
2. Bacon F (1620) Francis Bacon: the new Organon, or true directions for the interpretation of nature (Novum Organum). In: Jardine L, Silverthorne M (eds) (2000) Aphorisms, Book II, Chap. 29. Cambridge University Press, Cambridge, pp 102–221
3. Bateson W (1894) Materials for the study of variation, treated with especial regard to discontinuity in the origin of species. Macmillan, London, pp 85–86
4. Bateson W (1908) The methods and scope of genetics, Inaugural Lecture delivered 23 Oct 1908. Cambridge University Press, Cambridge
5. Bateson W (1913) Mendel’s principles of heredity, Chaps 4, 5 and 12. Cambridge University Press, Cambridge, pp. 77–87, 88–106, 212–216, 221
6. Beadle GW (1958) Genes and chemical reactions in Neurospora. In: Nobel Lectures including presentation speeches and laureates’ biographies. Physiology or Medicine, 1942–1962. Elsevier, Amsterdam, pp 587–597
7. Beadle GW, Ephrussi B (1937) Development of eye colors in Drosophila: diffusible substances and their inter-relations. Genetics 22:76–86
8. Boncinelli E (1997) Homeobox genes and disease. Curr Opin Genet Dev 7:331–337
9. Braun MM, Farag-El-Massah S, Xu K, Coté TR (2010) Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 9:519–522
10. Buckley BM (2008) Clinical trials of orphan medicines. Lancet 371:2051–2055
11. Chakrapani A, Holme E (2006) Disorders of tyrosine metabolism. In: Fernandes S, van den Berghe W (eds) Inborn metabolic diseases, diagnosis and treatment, 4th edn. Springer, Berlin, pp 233–243
12. Dietz HC (2010) New therapeutic approaches to mendelian disorders. N Engl J Med 363:852–863
13. Dolgin E (2010) Big pharma moves from ‘blockbusters’ to ‘niche busters’. Nat Med 16:837
14. European Committee for Orphan Medicinal Products (2011) European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov 10:341–349
15. Fernandez-Canon JM, Granadino B, Beltran-Valero de Bernabe D, Renedo M, Fernandez-Ruiz E, Penalva MA, Rodriguez de Cordoba S (1996) The molecular basis of alkaptonuria. Nat Genet 14:19–24. http://www.findakure.org/contact_us.php. Accessed 31 May 2011
16. Følling A (1934) ÜUber Ausscheidung von PhenylbrenztraubensÜaure in den Harn als Stoffwechselanomalie in Verbindung mit Imbe-zillitÜat. Hoppe-Seyler’s Zeitschrift Fuer Physiologische Chemie 227:169–176
17. Garrod AE (1901) About alkaptonuria. Lancet 2:1484–1486
18. Garrod AE (1902) The incidence of alkaptonuria: a study in chemical individuality. Lancet 2:1616–1620
19. Garrod AE (1909) Inborn errors of metabolism; the Croonian Lectures delivered before the Royal College of Physicians of London, in June, 1908. Henry Frowde, Hodder and Stoughton, Oxford University Press, London
20. Garrod AE (1924) The debt of science to medicine, Harveian oration, before the Royal College of Physicians on St Luke’s Day 1924. Clarendon, Oxford University, 30p
21. Garrod A (1928) The lessons of rare maladies: the Annual Oration delivered before the Medical Society of London on May 21st 1928. Lancet 211:1055–1060
22. Garrod AE (1931) The inborn factors in disease. Clarendon, Oxford University, London, p 65
23. Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA (2009) Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 96:20–26
24. Haffner ME (2006) Adopting orphan drugs – two dozen years of treating rare diseases. N Engl J Med 354:445–447
25. Harper PS (2005) William Bateson, human genetics and medicine. Hum Genet 118:141–151
26. Ingelfinger JR, Drazen JM (2011) Patient organisations and research on rare diseases. N Engl J Med 364:1670–1671
27. Introne WJ, Perry MB, Troendle J, Tsilou E, Kayser MA, Suwannarat P, O’Brien KE, Bryant J, Sachdev V, Reynolds JC, Moylan E, Bernardini I, Gahl WA (2011) A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab, E-pub, May, 6
28. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type 1 by inhibition of 4-hyroxyphenylpyruvate dioxygenase. Lancet 340:813–817
29. Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, Smith LL, Prisbylla MP, Mutter LC, Lee DL (1998) From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inherit Metab Dis 42:498–506
30. Mannoni A, Selvi E, Lorenzini S, Giorgi M, Airo P, Cammelli D, Andreotti L, Marcolongo R, Porfirio B (2004) Alkaptonuria, ochronosis, and ochronotic arthropathy. Semin Arthritis Rheum 33:239–248
31. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, Sarles J, de Baulny HO, Touati G (2008) NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 31:81–87
32. McKiernan PJ (2006) Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drug 66:743–750
33. Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, Gauthier M, Lacroix J, Vanasse M, Larbrisseau A et al (1990) Neurologic crises in hereditary tyrosinaemia. N Engl J Med 322:432–437
34. Mitchell GA, Grompe M, Lambert M, Tanguay RM (2001) Hyper-tyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Vogelstein B (eds) The metabolic and molecular bases of inherited disease (OMMBID), Chap 79, 8th edn. McGraw-Hill, New York, pp 1777–1805. http://www.ommbid.com. Modified 2002
35. Miyamoto BE, Kakkis ED (2011) The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet J Rare Dis 6:49
36. Moser AB, Borel J, Odone A, Naidu S, Cornblath D, Sanders DB, Moser HW (1987) A new dietary therapy for adrenoleukodys-trophy: biochemical and preliminary clinical results in 36 patients. Ann Neurol 21:240–249
37. Perry MB, Suwannarat P, Furst GP, Gahl WA, Gerber LH (2006) Musculoskeletal findings and disability in alkaptonuria. J Rheumatol 33:2280–2285
38. Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL, Anderson PD, Huizing M, Anikster Y, Gerber LH, Gahl WA (2002) Natural history of alkaptonuria. N Engl J Med 347:2111–2121
39. Santra S, Baumann U (2008) Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother 9:1229–1236
40. Sassa S, Kappas A (1983) Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevu-linic acid dehydratase activity by succinylacetone. J Clin Invest 71:625–634
41. Saunders ER, Bateson W (1902) The facts of Heredity in the light of Mendel’s discovery. Report of the Evolution Committee of the Royal Society 1:135
42. Saunders ER, Punnett RC, Bateson W (1905) Further experiments on inheritance in sweet peas and stocks. Proc R Soc Lond B 77:236–238
43. Saunders ER, Punnett RC, Bateson W (1906) Experimental studies in the physiology of heredity. Report to the Evolution Committee of the Royal Society 3:2–11
44. Saunders ER, Punnett RC, Bateson W (1908) Experimental studies in the physiology of heredity. Report to the Evolution Committee of the Royal Society 4:2–5
45. Sharma A, Jacob A, Tandon M, Kumar D (2010) Orphan drug: development trends and strategies. J Pharm Bioallied Sci 2:290–299
46. Srsen S, MÜuller CR, Fregin A, Srsnova K (2002) Alkaptonuria in Slovakia: thirty-two years of research on phenotype and genotype. Mol Genet Metab 75:353–359
47. Suwannarat P, O’Brien K, Perry MB, Sebring N, Bernardini I, Kaiser-KupferMI RBI, Tsilou E, Gerber LH, Gahl WA (2005) Use of nitisinone inpatients with alkaptonuria. Metabolism 54:719–728
48. Suzuki Y, Oda K, Yoshikawa Y, Maeda Y, Suzuki T (1999) A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria. J Hum Genet 44:79–84
49. Tatum EL (1958) A case history in biological research. In: Nobel Lectures including presentation speeches and laureates’ biographies. Physiology or Medicine, 1942–1962. Elsevier, Amsterdam. http://nobelprize.org/nobel_prizes/medicine/laureates/1958/. Accessed 9 July 2011
50. Wheldale M (1915) The anthocyanin pigments of plants, 1st edn. Cambridge University Press, Cambridge
51. Wheldale Onslow M et al (1981) The classical period in chemical genetics: recollections of Muriel Wheldale Onslow, Robert and Gertrude Robinson and J. B. S. Haldane Rose Scott-Moncrieff. Notes and Records of the Royal Society of London 36 (1):125–154
52. Wills R (1847) The works of W. Harvey (Transl). Sydenham Society, London, p 616